Novo Nordisk increased operating profit in local currencies by 13 percent and by 10 percent in Danish kroner to DKK 34.5 billion in 2014.
Sales growth of 8 percent in local currencies was driven by increased sales of Levemir® and Victoza®. Sales also increased by 6 percent in Danish kroner to 88.8 billion.
Gross margin improved by 0.5 percentage point in Danish kroner to 83.6 percent, driven by a favorable price development and a positive impact from product mix. Net profit increased by 5 percent to DKK 26.5 billion and diluted earnings per share increased by 8 percent to DKK 10.07.
For 2015, sales growth is expected to be 6-to-9 percent and operating profit growth is expected at around 10 percent, both measured in local currencies. Reflecting the appreciation of key invoicing currencies and the related currency hedging effects, operating profit as reported is projected to grow by approximately 29 percent, whereas pre-tax profit is expected to grow approximately 16 percent.
Source: Novo Nordisk
